Stoke Therapeutics (NASDAQ:STOK) Given Buy Rating at Chardan Capital

Chardan Capital restated their buy rating on shares of Stoke Therapeutics (NASDAQ:STOK) in a report released on Wednesday,Benzinga reports. Chardan Capital currently has a $24.00 target price on the stock.

A number of other research firms have also recently weighed in on STOK. Needham & Company LLC reaffirmed a “buy” rating and set a $22.00 price objective on shares of Stoke Therapeutics in a research report on Tuesday, July 1st. HC Wainwright lowered their price objective on shares of Stoke Therapeutics from $47.00 to $35.00 and set a “buy” rating for the company in a research report on Wednesday, May 14th. Jefferies Financial Group started coverage on shares of Stoke Therapeutics in a research report on Friday, July 18th. They issued a “buy” rating and a $30.00 price target for the company. Cantor Fitzgerald raised shares of Stoke Therapeutics to a “strong-buy” rating in a research report on Wednesday, May 14th. Finally, Wedbush raised their price target on shares of Stoke Therapeutics from $16.00 to $22.00 and gave the company an “outperform” rating in a research report on Wednesday. Six investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $25.17.

Stoke Therapeutics Stock Performance

NASDAQ:STOK opened at $16.91 on Wednesday. The stock has a market capitalization of $923.29 million, a P/E ratio of 19.89 and a beta of 1.15. The company has a 50 day moving average price of $12.28 and a 200 day moving average price of $10.06. Stoke Therapeutics has a fifty-two week low of $5.35 and a fifty-two week high of $17.61.

Stoke Therapeutics (NASDAQ:STOK) last posted its quarterly earnings data on Tuesday, August 12th. The company reported ($0.40) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.57) by $0.17. The firm had revenue of $13.82 million during the quarter, compared to analysts’ expectations of $31.51 million. Stoke Therapeutics had a net margin of 26.25% and a return on equity of 19.41%. Research analysts forecast that Stoke Therapeutics will post -2.01 earnings per share for the current fiscal year.

Insider Buying and Selling at Stoke Therapeutics

In other news, insider Barry Ticho sold 4,504 shares of the firm’s stock in a transaction on Friday, August 1st. The shares were sold at an average price of $12.82, for a total value of $57,741.28. Following the sale, the insider directly owned 16,775 shares in the company, valued at approximately $215,055.50. This trade represents a 21.17% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In the last quarter, insiders have sold 12,720 shares of company stock valued at $140,095. 9.50% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Stoke Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. JPMorgan Chase & Co. raised its holdings in shares of Stoke Therapeutics by 29.2% in the 4th quarter. JPMorgan Chase & Co. now owns 19,964 shares of the company’s stock valued at $220,000 after purchasing an additional 4,512 shares in the last quarter. GAMMA Investing LLC raised its holdings in shares of Stoke Therapeutics by 1,842.0% in the 1st quarter. GAMMA Investing LLC now owns 5,360 shares of the company’s stock valued at $36,000 after purchasing an additional 5,084 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in shares of Stoke Therapeutics by 123.7% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 95,505 shares of the company’s stock valued at $1,053,000 after purchasing an additional 52,813 shares in the last quarter. Renaissance Technologies LLC acquired a new stake in Stoke Therapeutics during the 4th quarter worth $1,423,000. Finally, ProShare Advisors LLC acquired a new stake in Stoke Therapeutics during the 4th quarter worth $139,000.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.